Bank of America’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-6,000
Closed -$120K 7199
2017
Q3
$120K Sell
6,000
-41,600
-87% -$814K ﹤0.01% 5605
2017
Q2
$873K Sell
47,600
-5,000
-10% -$67.4K ﹤0.01% 4522
2017
Q1
$518K Sell
52,600
-21,200
-29% -$257K ﹤0.01% 4866
2016
Q4
$805K Buy
73,800
+41,800
+131% +$439K ﹤0.01% 4494
2016
Q3
$448K Buy
+32,000
New +$260K ﹤0.01% 4704
2016
Q1
Sell
-380,500
Closed -$12.3M 7253
2015
Q4
$12.3M Buy
380,500
+100,300
+36% +$2.95M ﹤0.01% 2073
2015
Q3
$7.48M Buy
+280,200
New +$12M ﹤0.01% 2483

Other funds holding PTCT

Bank of America's PTCT Position: Q1 2026 in Review

Bank of America increased its PTC Therapeutics (PTCT) stake by 32% in Q1 2026, buying an estimated $32.2M and bringing the position to 1,886,841 shares worth $129M. The position accounts for 0.01% of the portfolio, ranked #956.

Bank of America first reported a position in PTCT in Q4 2013 and has held it in 50 quarters since. 351 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Bank of America held 1,886,841 shares of PTC Therapeutics worth $129M as of Q1 2026.
  • Bank of America bought 455,284 PTC Therapeutics shares in Q1 2026, an estimated $32.2M.
  • PTC Therapeutics made up 0.01% of Bank of America's portfolio in Q1 2026, its #956 holding.
  • Bank of America first reported a position in PTC Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.